Santhera's Transformation Should Turn Investors' Heads
DMD Drug To Be Filed With FDA Imminently
The Swiss biotech had a tough time after the failure of idebenone for Duchenne muscular dystrophy, but CEO Dario Eklund tells Scrip that with a new soon-to-be submitted compound, vamorolone, it has an effective and much safer alternative to steroids for the treatment of the progressive muscle degeneration genetic disorder.
